Exploring NLC Based Nanosuspension of Tyrosine Kinase Inhibitor for The Treatment of Head and Neck Cancer

Abstract

The rising cases of head & neck cancer & drawbacks of recently used clinically approved therapeutic strategies including salvage surgery along with adjuvant chemotherapy or chemo-radiotherapy have been inspired to pursuit improved therapeutic approaches. Various chemotherapeutic agents are being used which includes tyrosine kinase inhibitors, antimicrotubules monoclonal antibodies etc. from which tyrosine kinase inhibitors have been emerged as a convincing therapeutic strategy to suppress the tumor progression in head & neck cancer.Cabozantinib, sunitinib, vandetinib, imatinib, &sorafenib are the examples of tyrosine kinase inhibitors from which sorafenibinhibits the overexpression of tyrosine kinase receptors by targeting Raf/Mek/Erk in head &neck cancer. Sorafenib is a BCS class-2 drug due to which it showed very low solubility and reduced bioavailability at tumor site. To overcome these issues nanotechnology was introduced; the sorafenib loaded NLC based nanosuspension could successfully increased the solubility and permeability, enhance bioavailability and storage stability. As NLCs provide sustained and targeted drug release, the dose can be reduced which leads to decrease in the severe adverse effects. The aim of the study is to prepare sorafenib-loaded NLC based nanosuspensionto increase the bioavailability & therapeutic efficacy in head & neck cancer. Thus, sorafenib NLCs can be used as an alternative intervention for head & neck cancer chemotherapy because it acts through a different therapeutic mechanism from the presently available conventional treatment.